Levobupivacaína Kabi (Levobupivacaine Hydrochloride)

Levobupivacaine exerts its effect by binding to voltage‑gated sodium channels on neuronal membranes and stabilising them in an inactive configuration. This prevents the rapid influx of sodium ions that is necessary for depolarisation, thereby inhibiting the propagation of nerve impulses and producing a reversible loss of sensation and motor function in the region where it is administered.

The appropriate dose of Levobupivacaína Kabi is determined by the prescribing clinician based on the specific procedure, patient characteristics, and desired depth of anesthesia. Dosage regimens are individualized and should follow institutional protocols and the product’s prescribing information; patients should not adjust the dose without medical guidance.

Safety data for levobupivacaine in pregnancy are limited, and the drug should only be used when the potential benefit to the mother outweighs any possible risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug may be excreted in small amounts in breast milk, and a risk‑benefit assessment is required.

To place an order, submit an enquiry on the Levobupivácina Kabi product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then respond with pricing, availability, shipping details—including any cold‑chain requirements—and the necessary import documentation.

Levobupivacaine is the S‑enantiomer of bupivacaine and provides a similar duration of anesthesia with a lower risk of cardiotoxicity and central nervous system toxicity. Clinical studies suggest comparable efficacy for surgical and obstetric procedures, making levobupivacaine a preferred option when a safer cardiac profile is desired.

Levobupivácina Kabi should be stored at room temperature, below 25 °C, in its original packaging. The container must be kept closed, protected from light and moisture, and any unused portion should be discarded according to local regulations after the labeled expiry date.

The product is supplied as a sterile solution for epidural injection. Administration is performed by a qualified anesthesiologist or trained clinician using aseptic technique, typically through an epidural catheter placed in the lumbar or thoracic region. The dose is injected slowly while monitoring the patient’s cardiovascular and neurological status.

Serious adverse events include cardiac arrhythmias, seizures, severe respiratory depression, and allergic reactions such as anaphylaxis. Early recognition of symptoms—such as irregular heartbeat, loss of consciousness, difficulty breathing, or widespread rash—is essential, and immediate medical intervention should be initiated if any of these occur.

Levobupivácina Kabi is contraindicated in patients with known hypersensitivity to levobupivacaine or other amide‑type local anesthetics, in those with severe cardiac conduction disorders, and in individuals with uncontrolled epilepsy. Caution is also advised for patients with significant hepatic impairment, as drug clearance may be reduced.